Drug intelligence / Profile preview

daclatasvir + peginterferon alfa-2a + ribavirin

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Oral, Subcutaneous

Overview

Daclatasvir + peginterferon alfa-2a + ribavirin is an **oral/ injectable antiviral combination regimen** used in the treatment of chronic hepatitis C virus (HCV) infection. **Daclatasvir** is a small molecule inhibitor of the HCV NS5A protein, disrupting viral RNA replication and virion assembly. **Peginterferon alfa-2a** is a pegylated recombinant interferon that induces immune response and enhances antiviral activity via interferon-alpha receptor stimulation, and **ribavirin** is a nucleoside analog with broad-spectrum antiviral effects. Together, this combination acts by inhibiting multiple stages of the HCV life cycle and augmenting host immune activity. It has shown efficacy particularly in HCV genotype 1 and 4 infections, achieving improved sustained virologic response rates compared to peginterferon alfa-2a/ribavirin alone, and was in phase 2/3 development for these indications[1][2][3].

Brand names: Pegasys (pegylated interferon alfa-2a)Copegus (ribavirin)
Other names: daclatasvir plus peginterferon alfa-2a and ribavirin

Targets

vRNA (Coronavirus viral RNA)IFNAR (Immune system modulation via type I interferon receptor)NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))

Beyond the preview

Go deeper on daclatasvir + peginterferon alfa-2a + ribavirin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on daclatasvir + peginterferon alfa-2a + ribavirin.

Explore the full profile